Prospective comparison of simultaneous [<sup>68</sup>Ga]Ga-PSMA-11 PET/MR versus PET/CT in patients with biochemically recurrent prostate cancer.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 34374802.
- Also identified by DOI 10.1007/s00330-021-08140-0.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
PSMA-PET has become the PET technique of choice to localise the site of biochemically recurrent prostate cancer (PCa). With hybrid PET/MRI, the advantages of MRI are added to molecular characteristic of PET. The aim of this study was to investigate the incremental value of PET/MR versus PET/CT in patients with biochemically recurrent PCa by head-to-head comparison. Thirty-four patients with biochemically recurrent PCa were prospectively included. They underwent [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT, followed by simultaneous PET/MR. All PET (PET<sub>CT</sub>, PET<sub>MR</sub>), CT and MR images were evaluated for number of lesions and location. The number of lesions at specific sites was compared using Wilcoxon-sign-rank test. For PET, the maximum and mean standardised uptake values (SUVs) were calculated for each lesion compared using a two-sided paired t test. PET<sub>CT</sub> and PET<sub>MR</sub> scans were positive in 19 and 20 patients, detecting 73 and 79 lesions respectively. All lesions detected on PET<sub>CT</sub> were also detected on PET<sub>MR</sub>. CT and MRI only were positive in 14 and 17 patients, detecting 38 and 50 lesions, respectively, which was significantly lower than PET<sub>CT</sub> and PET<sub>MR</sub> respectively. Combined interpretation showed more lesions on PET/MR than on PET/CT (88 vs 81). No significant difference in detection of presence of local recurrence nor distant metastases was found. SUV<sub>mean</sub> and SUV<sub>max</sub> values were significantly higher on PET<sub>MR</sub> than on PET<sub>CT</sub> in local recurrence and lymph node metastases. [<sup>68</sup>Ga]Ga-PSMA-11 PET/MR was able to detect biochemically recurrent PCa at least as accurately as PET/CT for local recurrence, lymph node metastasis and distant metastasis. • PSMA PET/MRI detects the location of biochemical recurrence at least as accurately as PET/CT. • Substitution of PET/CT by PET/MRI adds sensitivity in PSMA lesion detection also in the setting of distant recurrence due to both the MR and TOF PET components.
Medical subject headings
- Positron Emission Tomography Computed Tomography
- Prostatic Neoplasms